Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib plus Topotecan for Recurrent Glioblastoma
NCT01931098Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2015
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib, topotecan in glioblastoma (GBM), sponsored by National Cancer Institute. Started Dec 2015; status: completed.
02
Drugs
pazopanibtopotecan
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01931098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01931098.